Through our blog, we hope to create a community where we can support and challenge each other through conversations, discussions and storytelling, and work together to move the field of oncology forward.

  • A new partnership to accelerate the potential of personalized monitoring in cancer

    This article was originally published on LinkedIn. ESMO is once again around the corner and with it comes the building anticipation for the data and discussions that will continue to shape the future of oncology. This year’s theme, Translating science into better patient care, is particularly pertinent for me …

    Continue Reading

  • More than two decades of work in oncology have shown me that cancer, especially advanced cancer, is often—and understandably—frightening and overwhelming, but developing the right, measured plan is key to helping patients navigate their treatment journeys with more reassurance, confidence, and success. And in my first …

    Continue Reading

  • The breadth of precision medicine at ASCO 2019

    The way ASCO started for me this year set the scene for what was an inspiring and fascinating weekend. Early on Friday morning, before most people’s ASCOs had started, I sat in a meeting room in the conference center watching it slowly fill to the brim with people. I was there to participate in a panel discussion on …

    Continue Reading

  • Looking at oncology – and ASCO – through a different lens

    This article was originally published on LinkedIn. It’s that time of year again, and I’m feeling a little shocked at the realization that a whole year has passed since I started sharing my perceptions and observations of the oncology landscape through this forum. It’s been a year of change for me professionally – a …

    Continue Reading

  • Pan-tumor biomarkers are key to some of today’s most remarkable cancer breakthroughs. One such biomarker is microsatellite instability (MSI), which plays an important role in immunotherapy treatment for advanced colorectal cancer patients. In the last four years, for example, the FDA approved two …

    Continue Reading

  • Uncovering Insights in Pancreatic and Prostate Cancers

    Most know a pancreatic cancer diagnosis is devastating. We’ve seen Patrick Swayze, Michael Landon, and Steve Jobs taken too soon by this terrible disease. We know survival is rare. Only 9 percent of patients live five years after diagnosis.1 Many may not realize, however, that prostate cancer can also be devastating, …

    Continue Reading

  • The Journal of the American Medical Association (JAMA) today published the validation study of our clinico-genomic database (CGDB), showing that real-world clinico-genomic data obtained during the course of routine patient care can yield scientifically and clinically meaningful insights. The study ‒ “Association of …

    Continue Reading

  • The most significant advances in cancer treatment start with a deep understanding of cancer biology; yet, even these biologically-driven hypotheses must be empirically validated given the complexity of the human body. This is why today immunotherapy treatments, which harness the power of our own immune systems, or …

    Continue Reading

  • Recognizing Value Through Collaboration

    As adoption of comprehensive genomic profiling (CGP) becomes more widespread in cancer treatment, new research is redefining the clinical utility of diagnostic tests in this age of precision medicine. The value of CGP lies in helping to inform decisions on available treatment options, including clinical trial …

    Continue Reading

  • Measuring the Value of Matched Therapy

    Broad molecular tumor profiling can offer clinical benefits to many cancer patients. This is further supported by the addition of broad genomic profiling to oncology practice guidelines, like the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in melanoma and non-small cell lung cancer (NSCLC). Now, …

    Continue Reading